September 16, 2020
Improved interdisciplinary collaboration with the adoption of Medalogix Care is driving expedited episode planning at home health admission
NASHVILLE, Tenn., (Sept. 14, 2020) Medalogix, the leading provider of data science in home health, announced today that Amedisys Home Health has reduced its days to bill RAP (Requests for Anticipated Payment) by 40 percent during the preliminary deployment of Medalogix Care. The Amedisys’ operations team is tracking this key performance indicator by measuring the time between patient admission and billing the RAP. This increase in efficiency is the result of collaborative, interdisciplinary communication facilitated by the use of Medalogix Care during the care planning process.
Designed to ensure that every patient receives the right level of care for their specific health needs, Medalogix Care provides objective, evidence-based recommendations that augment the knowledge that clinical teams use to make care planning decisions. Based on data science rooted in historical clinical data and known outcomes, Medalogix Care analyzes start of care and resumption of care OASIS data to recommend the optimal number of visits needed for each patient to safely discharge to community.
Agencies develop processes that ensure clinicians, in collaboration with the patient’s physician, will have final say over the number and type of visits patients receive. These processes facilitate collaboration between clinical care teams during the care planning process and, as a result, agencies leveraging Medalogix Care have reported a reduction in days to bill RAP.
“We’ve reduced the time to create a plan because the Medalogix Care recommendations require cross-team coordination that wasn’t always standard. This process is more efficiently aligning the team to the patient needs,” said Chris Gerard, Chief Operating Officer of Amedisys. “Further, we create a plan of care that is tailored specifically to each patient, which is more informed by our clinical team’s interdisciplinary experience and now supported by data.”
Medalogix Care augments the clinician’s decision-making process by elevating consideration of patient characteristics and historical clinical outcomes, not revenue. In some cases, fewer visits will be recommended, and in others, more visits; but in all scenarios the utilization recommendations are made with the singular focus of providing the right level of care to optimize clinical outcomes.
When included in this press release, words like “believes,” “belief,” “expects,” “plans,” “anticipates,” “intends,” “projects,” “estimates,” “may,” “might,” “would,” “should” and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform
Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to the following: changes in Medicare and other medical payment levels, our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively, changes in or our failure to comply with existing federal and state laws or regulations or the inability to comply with new government regulations on a timely basis, competition in the healthcare industry, our ability to integrate our personal care segment into our business efficiently, changes in the case mix of patients and payment methodologies, changes in estimates and judgments associated with critical accounting policies, our ability to maintain or establish new patient referral sources, our ability to attract and retain qualified personnel, changes in payments and covered services by federal and state governments, future cost containment initiatives undertaken by third-party payors, our access to financing, our ability to meet debt service requirements and comply with covenants in debt agreements, business disruptions due to natural disasters or acts of terrorism, our ability to integrate, manage and keep our information systems secure, our ability to comply with requirements stipulated in our corporate integrity agreement and changes in law or developments with respect to any litigation relating to the Company, including various other matters, many of which are beyond our control.
Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events. We expressly disclaim any obligation or undertaking and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law.
Amedisys, Inc. is a leading healthcare at home company delivering personalized home health, hospice and personal care. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based personal care; recovery and rehabilitation after an operation or injury; care focused on empowering them to manage a chronic disease; or hospice care at the end of life. We partner with 3,000 hospitals and 59,000 physicians nationwide that have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, Louisiana, with an executive office in Nashville, Tennessee, Amedisys is a publicly held company. With more than 17,900 employees, in 420 care centers in 34 states and the District of Columbia, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 369,000 patients in need every year. For more information about the Company, please visit: www.amedisys.com.
Medalogix is the only data science company focused exclusively on home health and hospice. The company was founded in 2012 with the desire to help home health agencies identify patients on census at-risk for unplanned rehospitalization. Since that time, Medalogix has developed products and services which help home health providers create clinical programs, manage large populations more efficiently, and drive value to strategic partnerships. Medalogix products have been recognized by Harvard Business Review, HIMSS, Fierce Healthcare, and Becker’s Hospital Review as innovative solutions for improving America’s healthcare system.
For more information, please visit Medalogix at http://medalogix.com/ or follow on Twitter at: @Medalogix.